Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ambiante Health & Wellness vs CoreAge Rx

By GLP-1 ScorecardUpdated

Ambiante Health & Wellness
Site position #496

Lower grade

CoreAge Rx
Site position #1

Higher grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 55/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +47
45
92
Dose & formulationCoreAge Rx +48
40
88
Clinical oversightCoreAge Rx +15
78
93
Labs & monitoringCoreAge Rx +37
53
90
FulfillmentCoreAge Rx +30
65
95
Contract termsCoreAge Rx +12
55
67
Ambiante Health & Wellness · top barCoreAge Rx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricAmbiante Health & WellnessCoreAge Rx
WeighScore55/10089.5/100
GradeCB+
Site position#496#1
SemaglutideNot disclosedProduct page from $79/mo; navigation $99. Confirm selected quote.
TirzepatideNot disclosedFrom $129/mo advertised; confirm selected charge, supply and renewal.
CoverageCoverage not publishedUS only; therapy-specific state restrictions apply
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Ambiante Health & Wellness

Site position #496 · C

Strengths

  • Compounded semaglutide and tirzepatide plus a low-dose GLP-1 "Longevity Microdose" option, all provider-guided
  • Concierge model: dedicated provider, direct secure messaging, provider-directed dosing, and structured check-ins
  • Every plan bundles compounded medication, provider care, and discreet direct delivery with no hidden fees
  • No charge if you are not approved; published support hours (Mon-Fri, 9am-5pm ET) by phone and email

What to consider

  • GLP-1 program pricing is not published on the site — quoted only after provider review, so cost is not comparable up front
  • Compounding pharmacy partners are not publicly named (a transparency gap for medication sourcing)
  • No brand-name Wegovy, Zepbound, Mounjaro, or Ozempic — compounded formulations only
  • State availability is not published; private-pay only, and the practice serves women, so it is not a fit for everyone
  • No LegitScript or PCAB accreditation displayed on the marketing site
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard